GSC
STML

Ground Swell Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

Ground Swell Capital’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Buy
+49
New +$603 ﹤0.01% 2261

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ground Swell Capital's STML Position: Q3 2014 in Review

Ground Swell Capital opened a new position in Stemline Therapeutics, Inc. (STML) in Q3 2014: 49 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2261 among its holdings.

61 funds tracked by Wall St. Rank hold STML as of Q3 2014.

  • Ground Swell Capital held 49 shares of Stemline Therapeutics, Inc. worth $1K as of Q3 2014.
  • Stemline Therapeutics, Inc. was a new Ground Swell Capital position in Q3 2014.
  • Stemline Therapeutics, Inc. made up ﹤0.01% of Ground Swell Capital's portfolio in Q3 2014, its #2261 holding.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.